格博生物获赛诺菲3000万美元战略股权投资

Core Insights - Gevo Bio announced a strategic equity investment of $30 million from Sanofi to support the development of two core projects, GLB-005 and GLB-007, aimed at treating sickle cell disease [1] Investment Details - The investment will facilitate the advancement of GLB-005 and GLB-007, both of which are expected to become disease-modifying therapies for sickle cell disease [1] - Sanofi has subscribed to newly issued preferred shares of Gevo Bio as part of the agreement [1] Licensing and Development Rights - Gevo Bio granted Sanofi a Right of First Negotiation (ROFN) for potential exclusive licensing negotiations related to the research, development, manufacturing, and commercialization of GLB-005 and GLB-007 [1] - The clinical phase I study for the products is anticipated to commence as early as the end of 2026 [1]